Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc's portfolio includes promising clinical-stage assets such as ALTO-207, which has shown significant improvements in patient outcomes during clinical trials, including favorable safety profiles and enhanced cognitive performance. Additionally, ALTO-300 aims to reduce liver toxicity while improving pharmacokinetics, showcasing the company's commitment to optimizing existing therapies for better efficacy. The acquisition of ALTO-207, which leverages established treatments and exhibits strong therapeutic effects, has further heightened investor interest and optimism surrounding the company's innovative approach to psychiatry.

Bears say

Alto Neuroscience faces significant challenges that contribute to a negative outlook on its stock, primarily derived from the high failure rates associated with clinical trials in depression, exacerbated by issues such as patient heterogeneity and high placebo response. Moreover, the company's reliance on critical patents for asset protection introduces additional risk; the potential non-issuance or dispute of these patents could lead to diminished market viability and a subsequent decrease in valuation. Lastly, noted adverse effects from study drugs, including nausea, dizziness, and lightheadedness, further complicate the development landscape and may undermine patient compliance and treatment efficacy.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.